

## **TOMASZ M. BEER, M.D., F.A.C.P.**

1604 SE 55<sup>TH</sup> Ave

Portland, OR 97215

608-590-8483 (office)

503-805-1981 (cell)

Email: [tom@tombeer.net](mailto:tom@tombeer.net)

Website: [www.tombeer.net](http://www.tombeer.net)



*Medical device executive, professor of medicine, clinician, and clinical, translational, and basic researcher in earlier cancer detection and prostate cancer. Former academic leader and senior health care executive responsible for strategic and operational leadership within an NCI-designated Comprehensive Cancer Center with responsibilities for oversight of the oncology service line, regional cancer network, interdisciplinary scientific programs, as well as shared scientific resources. Inventor, consultant, and business owner.*

## **PROFESSIONAL EXPERIENCE**

**2022 – Present**

**Exact Sciences Corporation**

Vice President, Chief Medical Officer for Multi-Cancer Early Detection (2022-present)

Responsible for the clinical development of blood-based multi-cancer early detection tests.

**1999 – Present**

**Oregon Health & Science University**

Faculty member (1999-present); Professor of Medicine with Tenure (2009-present)

Grover C. Bagby Chair for Prostate Cancer Research (2007-2022)

Built an internationally recognized clinical and translational research programs in earlier cancer detection and in prostate cancer. Led the successful development of enzalutamide for advanced prostate cancer from phase I through phase III trials and global approval. Patented a method to target the vitamin D receptor for cancer therapy, licensed the technology to Novacea, Inc. which, following a successful IPO, took the technology to a phase III trial together with license partner Schering-Plough. Led or participated in more than 150 clinical trials. Authored more than 280 publications, gave more than 100 invited presentations worldwide. Served on numerous national committees and working groups. Publications: <https://www.ncbi.nlm.nih.gov/pubmed/?term=beer+tm>

Deputy Director, OHSU Knight Cancer Institute (2009-2022)

The Knight Cancer Institute achieved Comprehensive Status in 2017 on the heels of a successful \$1B philanthropic campaign anchored by a historic \$500M challenge gift from Phil and Penny Knight. Responsible for oversight of the Cancer Institute's clinical enterprise, administration, operations, strategic planning, regional partnerships, and clinical research programs. Contributed to oversight of scientific programs as well as the design and execution of the landmark philanthropic campaign. Served on institutional leadership committees and represented the institute internally as well with external partners, media, and the public.

## Chief Medical Officer, Center for Early Detection Advanced Research (2017-2022)

Served as a member of the executive leadership team, representing clinicians and patients in the OHSU Knight Cancer Institute's premiere new initiative, a \$500M, 10-year program to advance the early detection of lethal cancer. Led early detection clinical trials group.

## **EDUCATION**

1986 B.A. The Johns Hopkins University  
1987 – 1988 Paul H. Nitze School of Advanced International Studies  
Graduate training in International Relations  
1991 M.D. The Johns Hopkins University School of Medicine (23 May 1991)  
1991 – 1994 Resident in Medicine, Oregon Health Sciences University  
1995 – 1996 Chief Resident in Medicine, Oregon Health Sciences University  
1996 – 1999 Fellow in Hematology and Medical Oncology, OHSU  
2005 The Foundation for Medical Excellence  
Health Care Leadership for the 21<sup>st</sup> Century – Institute One and Two  
2006 - 2007 OHSU Leadership Academy and Clinical Service Excellence Training  
2006 Real World Entrepreneurship  
2007 Harvard School of Public Health: Leadership Development for  
Physicians in Academic Health Centers

## **BUSINESS AND PROFESSIONAL ACTIVITIES**

### Consultant

- Serves on External Advisory Boards for Cancer Centers and Programs, Independent Data Safety Monitoring Committee for pivotal phase III clinical trials, and Scientific Advisory Boards for biopharmaceutical companies. Selected recent examples:
  - Arvinas, Inc. (2019-present); Serves on the Company Scientific Advisory Board focusing on advising the company on clinical development in cancer indications
  - Saliarius Pharmaceuticals LLC (2014-2018); Served on the Scientific Advisory Board in support of the development of a small molecule LSD1 inhibitor. In 2016, Saliarius successfully competed for a \$18.69 million New Company Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT)
  - OBR Oncology (2018 – present); Member, Editorial Board
  - Pelican Therapeutics, Inc. (2014-2017); Member of the Scientific Advisory Board in support of clinical development of strategies to target the co-stimulatory receptor TNFRSF25 as cancer immunotherapy. In 2016, Pelican successfully competed for a \$15.2 million New Company Product Development Award from CPRIT
- Advised early-stage biotechnology companies and large pharmaceutical companies on clinical development strategy for oncology drug candidates
- Provided advice and expert opinion on standards of care, best practices, scientific evidence, clinical decision making and outcomes in support of litigation
- Offered advice and analysis regarding current and future clinical trends in prostate cancer, and current and future drug products in support of investment and business decisions

### Business Owner

- 4246 LLC, Managing Partner (2007-present) Developed, operates commercial real estate
- Waverleigh Partners LLC, Partner (2005-present) Owns and operates multifamily housing
- Cascade Wax LLC, General Partner (2012-pres) Owns a consumer personal care business
- Urban Development + Partners, Limited Partner in a diversified urban development company (2011- present); Member, UDP Advisory Council (2019 – present)
- Summit Bank, Member, Portland Advisory Board (2021 – present)